CBIO vs PSA · $491.3M cap vs rev $4.82B
Crescent Biopharma, Inc. (CBIO) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Crescent Biopharma, Inc. (CBIO) is a biotechnology company listed on NASDAQ.
PSA (PSA) common stock.
CBIO does not have a complete income-statement cache yet.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
CBIO currently screens at market cap $491.3M. PSA currently screens at market cap $0.
Not investment advice. Open the CBIO and PSA stock pages for the full models.
Not investment advice.